Enoxaparin for outpatients with COVID-19 : 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial
Contributors
Voci, Davide; Götschi, Andrea; Held, UlrikePublished in
Thrombosis research, vol. 221, p. 157-163Publication date
2023-01First online date
2022-11-12Abstract
Keywords
- Anticoagulation
- COVID-19
- Heparin
- SARS-CoV2
- Thrombosis
- Venous thromboembolism
- Adult
- Humans
- Female
- Middle Aged
- Male
- Enoxaparin / therapeutic use
- SARS-CoV-2
- Outpatients
- Cardiovascular Diseases / drug therapy
- Anticoagulants / therapeutic use
- Treatment Outcome
UNIGE affiliation entities
UNIGE research groups
Citation (ISO format)
VOCI, Davide et al. Enoxaparin for outpatients with COVID-19 : 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial. In: Thrombosis research, 2023, vol. 221, p. 157–163. doi: 10.1016/j.thromres.2022.10.021
Main files (1)
Article (Published version)
Identifiers
- PID : unige:174233
- DOI : 10.1016/j.thromres.2022.10.021
- PMID : 36396519
- PMCID : PMC9657896
